Delcath Systems Inc. (DCTH)
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Delcath Begins Platform Expansion With Two Phase 2 Trials
Delcath's Q3 US sales hit $10 million. This unlocked $25 million in cash from its Tranche B Warrants, which will fund its Phase 2 trials for mCRC and mBC. HEPZATO KIT's hospital rollout is progressing well. Delcath plans to end the year with 15 centers and end 2025 with 30. Treatment has gone well at UCLA. Three retrospective clinical trials and the FOCUS trial's subgroup analysis add to the growing body of evidence which shows PHP's effectiveness in treating mUM and other tumor types.
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors.
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript
Delcath Systems Inc (NASDAQ:DCTH ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants Sudan Loganathan - Stephens Swayampakula Ramakanth - H.C. Wainwright John Newman - Canaccord Genuity Corp Yale Jen - Laidlaw & Company Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings and welcome to the Delcath Systems' Third Quarter 2024 Earnings Call.
Delcath Systems, Inc. (DCTH) Reports Q3 Loss
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.61 per share a year ago.
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 96.84%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 96.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why
Delcath Systems (DCTH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data
DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.
Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits
Delcath's HEPZATO KIT launch is gaining momentum, setting the company up for a strong 2025. My 2025 sales target is about double the consensus. The stock corrected after the Q2 report due to slower-than-expected hospital formulary acceptances, but Delcath is on track to reach 22 active centers in Q1 2025. ICC and mCRC are the next indications that will cement PHP's position as a platform technology. This will increase Delcath stock's multiple.
Delcath Systems Inc (DCTH) Q2 2024 Earnings Call Transcript
Delcath Systems Inc (NASDAQ:DCTH ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Conference Call Participants John Newman - Canaccord Genuity Corp Marie Thibault - BTIG Swayampakula Ramakanth - H.C. Wainwright Sudan Loganathan - Stephens Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to Delcath Systems' Second Quarter 2024 Earnings Conference Call.
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.58 per share a year ago.
